Diagnostic and treatment algorithm for different phenotypes of chronic rhinosinusitis with nasal polyps

  • Authors: Savlevich EL1, Dyneva ME2, Gaganov LE3, Egorov VI3, Gerasimov AN4, Kurbacheva OM2
  • Affiliations:
    1. Central State Medical Academy of Department for Presidential Affairs of the Russian Federation
    2. NRC Institute of Immunology FMBA ofRussia
    3. Moscow regional research clinical Institute M.F. Vladimirsky
    4. First Moscow State Medical University (Sechenov University)
  • Issue: Vol 16, No 2 (2019)
  • Pages: 50-60
  • Section: Articles
  • URL: https://rusalljournal.ru/raj/article/view/1198
  • DOI: https://doi.org/10.36691/RJA1198
  • Cite item
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Chronic rhinosinusitis with nasal polyps (CRSwNP) may vary in clinical manifestations and can often be associated with a number of comorbid diseases. For a practitioner it is important to forecast the development of the disease, evaluate the risk of relapse and select the most efficient method of treatment in each clinical case. At present, there are no standardized and validated diagnostic biomarkers that could be used as predictors of CRSwNP clinical course. Purpose of the study: to develop diagnostic and treatment algorithm for varies CRSwNP phenotypes based on clinical and laboratory parameters. Materials and methods, CRSwNP patients were split into 3 groups: group 1 - CRSwNP without allergy and asthma; group 2 - CRSwNP with allergic rhinitis and/or allergic asthma; group 3 - CRSwNP with non-allergic asthma. All patients were subjected to nasal cavity endoscopy and nasal polyps biopsy, allergological examination, histological analysis of polyp stroma to detect the leukocytes infiltration and eosinophil-neutrophil index (ENI). Results, CRSwNP phenotypes show significant difference in clinical manifestations of rhinosinusitis (p<0.005), eosinophil blood count (p<0.001), and polyps stroma leukocytes infiltration (p<0.004). At the same time, the combination of CRSwNP with allergic rhinitis, allergic and non-allergic asthma showed a more pronounced inflammatory response, which once again confirms the fact of the mutual influence of these pathological processes on each other. It was also found that the absolute eosinophil blood in peripheral blood does not correlate with the severity of eosinophilic cell infiltration degree in nasal polyps stroma, and, consequently, does not have correlate clinically relevant information on intensity of the local inflammatory response, contrary to previously proven relation between eosinophil count in blood and sputum in patients with asthma. Conclusion, Our study showed the feasibility of phenotyping CRSwNP depending on the comorbidity, which is a necessary tool in the selection of therapy in each case. Therefore, to improve the control and prevention of relapse of CRSwNP, a diagnostic and treatment algorithm for the management of patients depending on the phenotype of the disease is proposed.

Restricted Access

E L Savlevich

Central State Medical Academy of Department for Presidential Affairs of the Russian Federation

Email: savllena@gmail.com

M E Dyneva

NRC Institute of Immunology FMBA ofRussia

L E Gaganov

Moscow regional research clinical Institute M.F. Vladimirsky

V I Egorov

Moscow regional research clinical Institute M.F. Vladimirsky

A N Gerasimov

First Moscow State Medical University (Sechenov University)

O M Kurbacheva

NRC Institute of Immunology FMBA ofRussia

  1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I et al. European position paper on rhinosinusitis and nasal polyps. Rhinol Suppl. 2012;50(23):1-298. DOI: 10.2500/ ajra.2013.27.3925.
  2. Serrano E, Neukirch F, Pribil C, Jankowski R, Klossek JM et al. Nasal polyposis in France: impact on sleep and quality of life. J Laryngol Otol. 2005;119(7):543-549. doi: 10.1258/0022215054352108.
  3. Chung JH, Lee YJ, Kang TW, Kim KR, Jang DP et al. Altered Quality of Life and Psychological Health (SCL-90-R) in Patients With Chronic Rhinosinusitis With Nasal Polyps. Ann Otol Rhinol Laryngol. 2015;124(8):663-670. DOI: 0.1177/0003489415576181.
  4. Nordin S, Blomqvist EH, Olsson P Stjarne P Ehnhage A. Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyposis with asthma. Acta Otolaryngol. 2011;131(8):826-832. doi: 10.3109/00016489.2010.539625.
  5. Kim H, Han K, Kim SW Effect of chronic rhinosinusitis with or without nasal polyp on quality of life in South Korea: 5th Korea National Health and Nutrition Examination Survey Korean. Clin Exp Otorhinolaryngol. 2016;9(2):150-156. doi: 10.21053/ceo.2015.01053.
  6. Добрынин КБ. Эфферентные методы противорецидивного лечения при полипозном риносинусите. Российская оториноларингология. 2012; 61(6):50-55 УДК 616.211/.216.1-002.193-006.5:615.844.6.
  7. Lin DC, Chandra RK, Tan BK, Zirkle W. Conley DB et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J. Rhinol Allergy. 2011;25:205-208. doi: 10.2500/ajra.2011.25.3613.
  8. Asero R., Bottazzi G. Nasal polyposis: a study of its association with airborne allergen hypersensitivity. Ann Allergy Asthma Immunol. 2001;86:283-285. doi: 10.1016/S1081-1206(10)63299-1.
  9. De Corso E., Lucidi D., Battista M., Romanello M., De Vita C. et al. Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end? Int Forum Allergy Rhinol. 2017;7(9):861-867. doi: 10.1002/alr.21979.
  10. Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy Asthma Immunol Res. 2017;9(4):299-306. DOI: 10.4168/ aair.2017.9.4.299.
  11. Tokunaga T., Sakashita M., Haruna T., Asaka D., Takeno S. et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015;70(8):995-1003. doi: 10.1111/all.12644.
  12. Tosun F., Arslan HH, Karslioglu X. Deveci MS, Durmaz A. Relationship between postoperative recurrence rate and eosinophil density of nasal polyps. Ann Otol Rhinol Laryngol. 2010;119:455-459. doi: 10.1177/000348941011900705.
  13. Schleich FN1, Manise M., Sele J., Henket M., Seidel L., Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013;13:11. doi: 10.1186/1471-2466-13-11.
  14. Ненашева Н.М. Значение биомаркеров в диагностике и терапии бронхиальной астмы. Практическая пульмонология. 2017;4:3-9
  15. Schuler M., Faller H., Wittmann M., Schultz K. Asthma Control Test and Asthma Control Questionnaire: factorial validity, reliability and correspondence in assessing status and change in asthma control. J. Asthma. 2016;53(4):438-445. doi: 10.3109/02770903.2015.1101134.
  16. Меркулов ГА. Курс патогистологической техники. Л.: Медгиз. 1961:341
  17. Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J. Allergy Clin Immunol Pract. 2017;5(4):1061-1070. doi: 10.1016/j.jaip.2016.12.027.
  18. Mortuaire G., Gengler I., Balden M., Capron M., Lefevre G. Impact of allergy on phenotypic and endotypic profiles of nasal polyposis. European Annals of Otorhinolaryngology Head and Neck Diseases. 2017;135:159-162. DOI: 10.1016/j. anorl.2017.11.005.
  19. Tomassen P., Vandeplas G., Zele TV, Cardell LO, Arebro J. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J. Allergy Clin Immunol. 2016.137(5):1-8. doi: 10.1016/j.jaci.2015.12.1324.
  20. Савлевич ЕЛ, Курбачёва ОМ, Шачнев КН. Целесообразность применения иммунотропных препаратов в лечении хронического полипозного риносинусита. Российская ринология. 2018;26(3):41-46 doi: 10.17116/rosrino20182603141.
  21. Савлевич ЕЛ, Хайдуков СВ, Курбачёва ОМ, Бондарева ГП, Шачнев КН, Симбирцев АС. Показатели клеточного иммунитета пациентов с хроническим полипозным рино-синуситом. Медицинская иммунология. 2017;19(6):731-738 doi: 10.15789/1563-0625-2017-6-731-738.
  22. Курбачёва ОМ, Павлова КС. Аллерген-специфическая иммунотерапия: современные возможности. Астма и аллергия. 2015;(3): 16-20
  23. Rivero A., Jonathan L. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis. Annals of Otology, Rhinology & Laryngology. 2017;126(11)739-747. doi: 10.1177/0003489417731782.
  24. Федеральные клинические рекомендации по диагностике и лечению полипозного риносинусита Национальной ассоциации оториноларингологов. 2016. Доступно по: http://glav-otolar.ru/assets/images/docs/clinical-recomenda-tions/%D0%9A%D0%A0316%20%20Polipoznyj%20rinosi-nusit1.pdf
  25. Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(1):22-209. doi: 10.1002/alr.21695
  26. Савлевич ЕЛ, Егоров ВИ, Шачнев КН, Татаренко НГ Анализ схем лечения полипозного риносинусита в Российской Федерации. Российская оториноларингология. 2019;1(98):124-134 doi: 10.18692/1810-4800-2019-1-124-134.
  27. Савлевич ЕЛ, Гаганов ЛЕ, Егоров ВИ, Курбачёва ОМ, Герасимов АН, Шачнев КН. Сравнительное пилотное исследование эндотипов хронического полипозного риносинусита у пациентов, проживающих в разных географических регионах Российской Федерации. Иммунология. 2018;39(4):208-213 doi: 10.18821/0206-4952-2018-39-4-208-213.
  28. Lund VJ, MacKay V. Staging in rhinosinusitis. Rhinology 1993;31(4):183-184.
  29. Савлевич ЕЛ, Козлов ВС, Курбачёва ОМ. Современные тенденции диагностического поиска и терапии полипозного риносинусита. Российская ринология. 2018;26(2):41-47
  30. Bachert C, Mannent L, Naclerio RM et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469-479. DOI: 10.1001 / jama.2015.19330

Views

Abstract - 62

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2019 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies